Health economic evidence for the use of molecular biomarker tests in hematological malignancies: A systematic review

Martin Vu1,2 | Koen Degeling1,2 | Ella R. Thompson3,4 | Piers Blombery3,4,5 | David Westerman3,4,5 | Maarten J. IJzerman1,2,6,7

1Cancer Health Services Research, Centre for Cancer Research, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Australia
2Cancer Health Services Research, Centre for Health Policy, Melbourne School of Population and Global Health, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Australia
3Pathology Department, Peter MacCallum Cancer Centre, Melbourne, Australia
4Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia
5Clinical Haematology, Peter MacCallum Cancer Centre/Royal Melbourne Hospital, Melbourne, Australia
6Department of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Australia
7Health Technology and Services Research, Faculty of Behavioural, Management and Social Sciences, Technical Medical Centre, University of Twente, Enschede, The Netherlands

Abstract

Objectives: Molecular biomarker tests can inform the clinical management of genomic heterogeneous hematological malignancies, yet their availability in routine care largely depends on the supporting health economic evidence. This study aims to systematically review the economic evidence for recent molecular biomarker tests in hematological malignancies.

Methods: We conducted a systematic search in five electronic databases for studies published between January 2010 and October 2020. Publications were independently screened by two reviewers. Clinical study characteristics, economic methodology, and results were extracted, and reporting quality was assessed.

Results: Fourteen studies were identified, of which half (n=7; 50%) were full economic evaluations examining both health and economic outcomes. Studies were predominantly conducted in a first-line treatment setting (n=7; 50%) and adopted a non-lifetime time horizon to measure health outcomes and costs (n=7; 50%). Five studies reported that companion diagnostics for associated therapies were likely cost-effective for acute myeloid leukemia, chronic myeloid leukemia, diffuse large B-cell lymphoma, and multiple myeloma. Four studies suggested molecular biomarker tests for treatment monitoring in chronic myeloid leukemia were likely cost-saving.

Conclusions: Although there is initial confirmation of the promising health economic results, the present research for molecular biomarker tests in hematological malignancies is sparse with many applications of technological advances yet to be evaluated.

KEYWORDS
cost-effectiveness, costs, health services, hematological malignancies, molecular biomarker

Novelty statement
This systematic review synthesized and appraised the health economic evidence for molecular biomarker tests in hematological malignancies. Although several molecular biomarker tests represent cost-effective and cost-saving use of health resources, more studies are required to provide further health economic evidence on the promising and emerging application of these technologies across hematological malignancies. By doing so, health economic research in this area can further support payor reimbursement and access of molecular biomarker testing services for patients with a hematological malignancy.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2022 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd.
Collectively, hematological malignancies were the fourth most commonly diagnosed cancer worldwide in 2020 and responsible for a significant cancer burden.\(^1\) The 5-year survival from diagnosis in the United States (US) is 64% for leukemias, 87% for Hodgkin lymphomas, 73% for non-Hodgkin lymphomas, and 54% for myelomas, and challenges remain in managing relapsed disease and the long-term effects of cancer treatments on patients.\(^2-4\) The economic cost of hematological malignancies is substantial, estimated at $12 billion in Europe 2012 arising from direct healthcare consumption, productivity losses, and informal care.\(^5\) This all emphasizes the importance of providing better treatments and controlling overall costs.

Molecular biomarker tests are assisting clinicians to optimize treatment strategies specific to the molecular profile for each individual patient.\(^6-8\) The benefit for molecular biomarker tests to personalize treatment and improve patient outcomes is demonstrated across numerous predictive and prognostic applications and is consequently endorsed by several clinical guidelines. This includes testing for the TP53 mutations and IGHV somatic hypermutation in predicting response to chemotherapy for chronic lymphocytic leukemia (CLL)\(^9\) and testing for the ASXL1, CEBPA, FLT3, NPM1, RUNX1, and TP53 gene mutations for refining diagnosis in acute myeloid leukemia (AML).\(^10\) Several targetable gene mutations such as FLT3, IDH1, and IDH2 in AML are also clinically recognized important predictive biomarkers for treatment selection.\(^11\) There are many different types of genetic and genomic technologies that are used to detect actionable molecular changes in hematological malignancies, including next-generation sequencing (NGS) platforms for targeted DNA sequencing and whole-genome sequencing (WGS) and whole-exome sequencing (WES), but they vary in their technical and analytical capacities.\(^12-13\) However, technological advancements for clinical decision making are not being matched by their uptake in the health system.\(^6,8,14-16\)

Health economic considerations regarding the cost-effectiveness of molecular biomarker tests are pivotal in overcoming regulatory policy hurdles that have traditionally prohibited payor coverage and reimbursement to these services. In this regard, health technology assessments (HTA) of new medical products guide payor decisions concerning their benefits, harms, and costs to patients and society. Both as HTA mainstays, economic evaluations inform allocation of health resources that will maximize population benefits whereas budget impact analysis assesses the consequences of an intervention on resource consumption and costs.\(^17,18\) Understanding the available economic evidence is important to support reimbursements and widespread use of accurate and reliable molecular biomarkers tests, such as NGS testing. It is necessary to consider these health economic aspects to highlight potential gaps between clinical and economic evidence. Therefore, the objective of this systematic review was to (i) identify and appraise the current health economic evidence for molecular biomarker tests used for the clinical care of hematological malignancies.

### MATERIALS AND METHODS

This systematic review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (International Prospective Register of Systematic Reviews [PROSPERO] registration number CRD42020212798).

#### 2.1 Eligibility criteria

Publications were included if target population comprised of patients with a hematological malignancy irrespective of age, gender, stage, or treatment received. Publications had to evaluate at least one of the following technology platforms: karyotyping, fluorescence in situ hybridization (FISH), single nucleotide polymorphism microarray, polymerase chain reaction (PCR)-based techniques (e.g., real-time quantitative polymerase chain reaction [qPCR]), reverse transcriptase polymerase chain reaction (RT-PCR), or quantitative reverse transcriptase PCR (RT-qPCR), gene expression profiling (e.g., gene expression microarray or WTS), or DNA sequence analysis (e.g., Sanger sequencing, targeted DNA sequencing, whole-exome sequencing [WES] or WGS). Trial-based or model-based economic analyses that were either full or partial economic evaluations (i.e., cost analysis, cost-consequence, cost-minimization, cost-effectiveness, cost-utility, cost-benefit), or a budget impact analysis, comparing at least two alternative interventions, were considered. Only publications in the past decade were included to maintain relevancy with current clinical practice. Publications that involved non-malignant hematological diseases or did not report on health economic indicators, as well as conference papers, abstracts, or reviews, or not published in English, were excluded.

#### 2.2 Search strategy

A systematic search was conducted using the Ovid\(^\circ\) platform for electronic databases consisting of MEDLINE, Embase, Cochrane Library (Cochrane), Health Technology Assessment, and National Health Services Health Economic Evaluation Database (NHSEED). Each database was individually searched from January 1, 2010, up until October 9, 2020. The search strategy consisted of free key words and subject headings related to blood cancers, molecular biomarker tests, and health economic studies. Medical subject headings (MeSH) were used for MEDLINE, Cochrane, Health Technology Assessment, and NHSEED databases, while Embase subject headings (EMTREE) were used for the Embase database. Full search strategy for each database is available in Tables S1-S5.

#### 2.3 Study selection

After removing duplicates, study selection occurred in two stages and a publication was excluded if it did not meet one or more of...
the eligibility criteria. Initially, two reviewers (M.V. and K.D.) independently performed title and abstract screening for the first 10% of publications identified, with no differences in the inclusion of publications between both reviewers. For the remaining 90% of publications, title and abstract screening was completed by one reviewer (M.V.). All full-text publications were then independently assessed by two reviewers (M.V. and K.D.) for eligibility. Disagreement regarding publication eligibility was resolved through consensus.

2.4 Data extraction and synthesis

One reviewer (M.V.) read the full-text and supplemental materials to extract relevant study and methodological data using a prespecified extraction template. General article and clinical information were extracted for year of publication, journal of publication according to specialist area (i.e., clinical, or economic or HTA journal), funding classification (i.e., non-industry or industry funding), country of evaluation, study population, primary hematological malignancy, molecular biomarkers and technology testing platform, purpose of the test (i.e., prognosis, diagnosis, treatment selection, dosing, monitoring), treatment line, and treatment received (where applicable). If there was no information regarding funding sources from the publication, funding classification was based on the affiliation of the primary author. The European Society of Medical Oncology (ESMO) guidelines were used as a reference for clinically relevant molecular testing strategies to investigate whether all endorsed strategies have been evaluated. The incidence of each hematological malignancy for included studies was assessed based on 2019 Global Burden of Disease data.

Data extraction for methodological information included type of health economic study, whether a decision analytic model was used, study perspective, time horizon, annual discount rate, currency and currency index year, economic and effectiveness outcomes considered, economic and effectiveness data sources, willingness-to-pay thresholds, validation efforts, and sensitivity and uncertainty analyses. For publications with a decision analytic model, model-specific characteristics were assessed, including type of decision analytic model, model structure, cycle length (if applicable), and structural and methodological assumptions reported. Economic and/or effectiveness results per strategy, including the incremental cost-effectiveness ratio (ICER), were also reported.

Economic outcomes were converted to 2020 US dollars (US$) by adjusting for inflation to the year 2020 using the average Organization for Economic Co-operation and Development (OECD) Consumer Price Index (CPI) for the country reported in the study and then an exchange rate to 2020 US$ using the average OECD Purchasing Power Parity (PPP) conversion factor. If no index year for economic effects, a recent index year was used.

FIGURE 1 PRISMA flowchart diagram of publication selection process including reasons for exclusion.
# Overview of study characteristics, clinical and intervention considerations, and health and economic outcomes

| Publication | Study characteristics | Country | Perspective, time horizon | Test purpose | Strategies evaluated |
|-------------|-----------------------|---------|---------------------------|--------------|----------------------|
| **ALL (n = 1)** | | | | | |
| Donnan et al. (2011) | Cost-effectiveness analysis | Canada | Healthcare system, 3 months | Treatment dosage | a. No test (weight-based dosing)  
b. Enzymatic test  
c. TPMT genotype test |
| **AML (n = 2)** | | | | | |
| Cressman et al. (2016) | Cost-utility analysis | Canada | Healthcare system, 10 years | Treatment selection | a. Standard molecular analysis of 3 genes  
b. Targeted genomic analysis of 10 genes |
| Hörster et al. (2017) | Cost-effectiveness analysis | Germany | Healthcare system, 10 years | Treatment selection | a. Conventional cytogenetics diagnostics  
b. Molecular genetic diagnostics |
| **CLL (n = 2)** | | | | | |
| Al Zaabi et al. (2010) | Cost analysis | Canada | Health service, not reported | Prognostication | a. FISH  
b. MLPA |
| Buchannan et al. (2017) | Cost-effectiveness analysis and cost-utility analysis | UK | Healthcare system, 30 years (lifetime) | Treatment selection | a. No genetic test (ibrutinib)  
b. Genetic test (ibrutinib)  
c. Genetic test (refractory ibrutinib treatment)  
d. Genomic test (first-line ibrutinib in chemoimmunotherapy non-responders)  
e. Genomic test (refractory ibrutinib in chemoimmunotherapy non-responders) |
| **CML (n = 6)** | | | | | |
| Cayuella et al. (2011) | Cost-minimization analysis | France | Societal, not reported | Treatment monitoring | a. Non-automated RT-qPCR (dedicated equipment)  
b. Non-automated RT-qPCR (shared equipment)  
c. Automated RT-qPCR |
| Gautney et al. (2011) | Cost-effectiveness analysis and cost-utility analysis | Netherlands | Healthcare system, 2 years | Treatment selection | a. No test (dasatinib)  
b. Microarray |
| Molecular biomarker(s) | Treatment line | Treatment type | Cost (2020 US$) | Effectiveness | Conclusions |
|-----------------------|----------------|----------------|-----------------|---------------|-------------|
| **TPMT**              | Not reported   | Chemotherapy   | a. $655         | a. 0.25 LY    | TPMT genotype test for chemotherapy treatment dosing in pediatric ALL is associated with no survival benefit at a higher cost compared to no test (weight-based dosing) strategy. |
| **FLT3-ITD, NPM1, CEBPA, IDH1, IDH2, TET2, KMT2A, PTD, PHF6, ASXL1, DNMT3A** | First-line | Chemotherapy and HSCT | a. $144 738 | a. 3.48 QALY | Targeted genomic analysis of 10 genes for treatment selection in AML is likely cost-effective compared to standard molecular analysis at a willingness-to-pay of CAD$100,000 per QALY in Canada. |
| **FLT3-ITD, NPM1, CEBPA** | First-line | Chemotherapy and HSCT | a. $93 498 | a. 0.94 LY | Molecular genetic diagnostics for treatment selection in AML is likely cost-effective compared to conventional cytogenetic diagnostics at a willingness-to-pay between simple and three times GDP per capita in Germany. |
| del(2p), del(6q), del(8q), del(9p), del(10q), del(11q), del(12p), del(13q), del(17p), +12 | Previously untreated and treated (not otherwise specified) | Not applicable | a. $328 | Not applicable | FISH for prognostication in CLL cost more than MLPA. |
| **TP53**              | All            | Chemo-immunotherapy, BTK inhibitors and HSCT | a. $107 920 | a. 6.37 LY/5.60 QALY | Genomic test strategies for treatment selection in CLL is not cost-effective compared to no genetic test strategy at a willingness-to-pay threshold of £30,000 per QALY in the UK. |
| **BCR-ABL1**          | Not reported   | TKI therapy    | a. $168         | Not applicable | Automated RT-qPCR for treatment monitoring in CML cost more than non-automated RT-qPCR at an annual activity level greater than 300 cases. |
| **T315I**             | Second-line    | TKI therapy, chemotherapy and HSCT | a. $151 798 | a. 1.74 PFLY/1.61 QALY | Microarray platform for treatment selection in CML is cost-effective (greater health gains at a lower cost) compared to no test strategy in the Netherlands. |
TABLE 1 (Continued)

| Publication                  | Health economic analysis type | Country            | Perspective, time horizon | Test purpose                          | Strategies evaluated                                                                 |
|------------------------------|-------------------------------|--------------------|---------------------------|---------------------------------------|--------------------------------------------------------------------------------------|
| Guérin et al. (2014)         | Cost analysis                 | US                 | Healthcare system, 1 year | Treatment monitoring                  | a. 0 qPCR test per year  
   b. 1-2 qPCR tests per year  
   c. 3-4 qPCR tests per year |
| Latremouille-Viau et al. (2017) | Cost analysis                | US                 | Healthcare system, 1 year | Treatment monitoring                  | a. 1 qPCR test per year  
   b. 2 qPCR tests per year  
   c. 4 qPCR tests per year |
| Jabbour et al. (2018)        | Cost analysis                 | US                 | Payor, not reported       | Treatment monitoring                  | a. 0 RT-qPCR test per year  
   b. 3 RT-qPCR test per year |
| Yamazaki et al. (2020)       | Budget impact analysis        | Japan              | Payor, 3 years            | Treatment monitoring                  | a. Quarterly RT-qPCR tests (TKI continuation strategy)  
   b. Quarterly RT-qPCR tests during treatment followed by monthly RT-qPCR tests for treatment-free remission eligible patients in the first year and then quarterly thereafter (TKI discontinuation strategy) |

Non-Hodgkin lymphoma (DLBCL, FL) and Hodgkin lymphoma (n = 1)

Costa et al. (2016)  
Cost analysis  
Canada  
Health service, not reported  
Prognostication  
a. Targeted capture sequencing (DLBCL and FL patients)  
b. Digital gene expression profiling (DLBCL and Hodgkin lymphoma patients)  
c. FISH (DLBCL patients)

DLBCL (n = 1)

Chen et al. (2018)  
Cost-utility analysis  
US  
Payor, lifetime  
Treatment selection  
a. No test (chemotherapy)  
b. No test (R2CHOP treatment)  
c. Gene expression profile test

MM (n = 1)

Gaultney et al. (2018)  
Cost-utility analysis  
Multiple European countries  
Healthcare system, lifetime  
Treatment selection  
a. No test (bortezomib-based regimens)  
b. International Staging System and FISH  
c. SKY92 signature test  
d. International Staging System, FISH and SKY92 signature test

Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BTK, Bruton tyrosine kinase; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; DLBCL, diffuse large B-cell lymphoma; FISH, fluorescence in situ hybridization; FL, follicular lymphoma; HSCT, hematopoietic stem cell transplant; LY, life years; MLPA, multiplex ligation-dependent probe amplification; MM, multiple myeloma; PFLY, progression free life year; QALY, quality-adjusted life years; qPCR, quantitative real-time polymerase chain reaction; R2CHOP, lenalidomide plus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; RT-qPCR, reverse transcription quantitative polymerase chain reaction; TKI, tyrosine kinase inhibitor; UK, United Kingdom.

Health economic outcomes are reported as discounted costs and effectiveness where appropriate.
| Molecular biomarker(s) | Treatment line | Treatment type | Cost (2020 US$) | Effectiveness | Conclusions |
|-----------------------|----------------|----------------|----------------|--------------|-------------|
| **BCR-ABL1**          | First-line     | TKI therapy    | a. $20,539     | Not applicable | Regular treatment monitoring of BCR-ABL1 transcripts in CML via qPCR is associated with lower healthcare costs. |
|                       |                |                | b. $18,827     |              |             |
|                       |                |                | c. $16,712     |              |             |
| **BCR-ABL1**          | First-line     | TKI therapy    | Not reported   | Not applicable | Regular treatment monitoring of BCR-ABL1 transcripts in CML via qPCR is associated with lower healthcare costs. |
|                       |                |                |                |              |             |
| **BCR-ABL1**          | First-line     | TKI therapy    | a. $7,372      | Not applicable | Regular treatment monitoring of BCR-ABL1 transcripts in CML via RT-qPCR is associated with lower healthcare costs. |
|                       |                |                | b. $1,206      |              |             |
| **BCR-ABL1**          | First and second-line | TKI therapy | a. $148,383,396 | Not applicable | Increased treatment monitoring of BCR-ABL1 transcripts in CML via RT-qPCR in treatment-free remission eligible patients (TKI discontinuation strategy) is associated with cost saving compared to regular quarterly monitoring for all patients (TKI continuation strategy). |
|                       |                |                | b. $74,659,666 |              |             |

Although full list of molecular biomarkers not reported, study specified number of genes for each panel and FISH break-apart probes used in genetic analysis:

| Molecular biomarker(s) | Treatment line | Treatment type | Cost (2020 US$) | Effectiveness | Conclusions |
|-----------------------|----------------|----------------|----------------|--------------|-------------|
| Not reported          | First-line     | Chemotherapy and chemoimmuno-therapy | a. $940      | Not applicable | Targeted capture sequencing for prognostication in DLBCL and FL cost more than digital gene expression profiling (DLBCL and Hodgkin lymphoma) and FISH (DLBCL). |
|                       |                |                | b. $821       |              |             |
|                       |                |                | c. $545       |              |             |

Gene expression profile test for treatment selection in DLBCL is likely cost-effective compared to no test (chemotherapy) strategy in the US although factors such as treatment survival benefit and cost are likely to influence findings:

| Molecular biomarker(s) | Treatment line | Treatment type | Cost (2020 US$) | Effectiveness | Conclusions |
|-----------------------|----------------|----------------|----------------|--------------|-------------|
| t(4;14), del(17p), SKY92 signature | First-line | Chemotherapy, proteasome inhibitor | a. $302,225–$508,982 | 4.24–4.72 QALY | International Staging System and FISH and/or SKY92 signature test for treatment selection in MM is cost-effective (greater health gains at a lower cost) compared to no test strategy across multiple European countries. |
|                       |                |                | b. $282,981–$455,246 | 4.24–4.73 QALY |             |
|                       |                |                | c. $327,445–$465,878 | 4.27–4.76 QALY |             |
|                       |                |                | d. $289,046–$463,967 | 4.26–6.76 QALY |             |
outcomes was reported, the year prior to the publication was used instead. Likewise, if the currency was not specified, it was assumed that the currency is based on the country of publication.

2.5 | Quality assessment and risk of bias

One reviewer (M.V.) assessed the publication quality using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist. The CHEERS checklist provides a minimum set of health economic study aspects that should be reported. Each publication was scored under each criteria item, being awarded a score of 1 if a criterion was satisfactorily reported and a score of 0 if unsatisfactorily reported. Depending on the study, not all items were applicable, and so no score was given for that item. When there was scoring doubt, the input of a second reviewer (K.D.) was conferred. Overall reporting compliance was calculated based on proportion of satisfactory criteria items compared to the total number of applicable criteria items in the checklist.

Risk of bias was not assessed as no established risk of bias assessment tools currently exist for health economic studies.

3 | RESULTS

The PRISMA diagram presented in Figure 1 details the selection of publications under each review stage. The search strategy identified 1453 unique publications, of which 1375 were excluded following title and abstract screening. Of the remaining 78 publications, 64 publications were excluded based on full-text review. Finally, 14 publications met the inclusion criteria and were included in this review.

3.1 | General characteristics

Table 1 outlines the general study characteristics and health and economic outcomes, grouped by primary hematological malignancy. Nine (64%) of the fourteen studies were published between 2015 and 2020, while five (36%) studies were published between 2010 and 2014. The country of evaluation was mostly from Canada or the US (both n = 4; 29%). Majority of studies were published in a clinical journal (n = 11; 79%) rather than an economic or HTA journal (n = 3; 21%). More studies declared non-industry (i.e., government, non-government, and academia) funding (n = 8; 57%) compared to industry funding (n = 6; 43%).

3.2 | Reporting quality

Figure 2 presents the percentages of publications that have satisfactorily reported applicable CHEERS checklist item, and a more detailed scoring for each publication is provided in Table S6. Reporting compliance ranged between 42% and 100% with a median CHEERS score of 90%. Most studies (n = 10; 71%) were categorized as high reporting quality (CHEERS score >80%). Patient preferences and characterizing heterogeneity were not applicable for many publications since studies did not seek to elicit preferences nor...
| Hematological malignancy       | 2019 GBD incidence rates per 100 000 | Chromosomal aberrations | Gene mutations |
|-------------------------------|-------------------------------------|--------------------------|----------------|
| ALL                           | 1.98                                | −7, −8, +19q(2), −21q, −22q, +del(7p), +del(11q), +del(17p) | ABL1, CEP2, CREBP, FRK, W2, FIT3, HKF1, JAK2, KRAS, NFE, NOTCH1, NRAS, POG-F, RAS, PHT1, TET3 |
| AML                           | 1.61                                | −5, −7, −del(17p)         | ASX1, CEP2, EITF, IDH1, IDH2, KMT2A, KMT2B, KMT2D, PHE, AS6, AS1, DNMT3A |
| Myelodysplastic, myeloproliferative, and other hematopoietic neoplasms | 5.20                                | +del(7p), +8, +19q(2), +22q, +del(11q), +del(17p) | BCR-ABL1, T315I |
| CML                           | 0.85                                | +del(7p), +12, +del(17p)  | No chromosomal aberrations included in review |
| Other leukemia                | 5.00                                | +8, +19, +22q, +del(7p)   | No chromosomal aberrations included in review |
| Hodgkin lymphoma              | 2.50                                | +8, +19, +22q, +del(7p)   | No chromosomal aberrations included in review |
| Non-Hodgkin lymphoma          | 1.34                                | +8, +19, +22q, +del(7p)   | No chromosomal aberrations included in review |
| MM                            | 2.01                                | +del(7p), +12, +del(17p), +del(19q) | No chromosomal aberrations included in review |

**TABLE 2** Summary of hematological malignancy incidence and molecular biomarkers clinically recommended and evaluated by health economic studies

**Abbreviations:** ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; DLBCL, diffuse large B-cell lymphoma; ESMO, European Society for Medical Oncology; FL, follicular lymphoma; GBD, Global Burden of Disease; HCL, hairy cell leukemia; MCL, mantle cell lymphoma; MDS, myelodysplastic syndrome; MM, multiple myeloma; MPN, myeloproliferative neoplasm; MZL, marginal zone lymphoma; PCL, primary cutaneous lymphoma; PMBCL, primary mediastinal large B-cell lymphoma; PTCL, peripheral T-cell lymphoma; WM, Waldenström’s macroglobulinemia.

Hematological malignancy classified according to causes of diseases used by 2019 GBD.
### TABLE 3  Methodological and decision analytic model characteristics including reporting quality assessment of publications

| Publication | Economic analysis | Model structure | Cycle length |
|-------------|-------------------|-----------------|--------------|
| **ALL (n = 1)** | | | |
| Donnan et al. (2011) | Decision tree model | Health: adverse drug events and severity | Not applicable |
| **AML (n = 2)** | | | |
| Cressman et al. (2016) | Decision tree and state-transition cohort model | Health: relapse, complete remission, death | 90 days |
| Hörster et al. (2017) | State-transition cohort model | Health: induction, remission, relapse, death | 1 month |
| **CLL (n = 2)** | | | |
| Al Zaabi et al. (2010) | Not applicable | Not applicable | Not applicable |
| Buchannan et al. (2017) | State-transition cohort model | Health and treatment | 28 days |
| **CML (n = 6)** | | | |
| Cayeuella et al. (2011) | Not applicable | Not applicable | Not applicable |
| Gaultney et al. (2011) | Decision tree model | Health: treatment response and PD | Not applicable |
| Guérin et al. (2014) | Not applicable | Not applicable | Not applicable |
| Latremouille-Viau et al. (2017) | Not applicable | Not applicable | Not applicable |
| Jabbour et al. (2018) | Decision tree model | Health: PD | Not applicable |
| Yamazaki et al. (2020) | State-transition cohort model | Health and treatment | 1 year |
| **Non-Hodgkin lymphoma (DLBCL, FL) and Hodgkin lymphoma (n = 1)** | | | |
| Costa et al. (2016) | Not applicable | Not applicable | Not applicable |
| **DLBCL (n = 1)** | | | |
| Chen et al. (2018) | State-transition patient model | Health: PFS, relapse, death | 3 weeks |
| **MM (n = 1)** | | | |
| Gaultney et al. (2018) | State-transition cohort model | Health: PFS, PD, death | 1 month |

Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CHEERS, Consolidated Health Economic Evaluation Reporting Standards; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MM, multiple myeloma; PD, progressive disease; PFS, progression free survival.

perform subgroup analysis. Not all model-based studies provided justification to model choice (n = 4; 29%).31,32,35,36

#### 3.3 | Clinical test application

Studies analyzed the impact of molecular biomarker tests across numerous hematological malignancies, including chronic myeloid leukemia (CML) (n = 6, 43%),28,31,32,34,36,37 AML (n = 2: 14%),25,27 and CLL (n = 2; 14%).26,33 Single studies (each 7%) considered acute lymphoblastic leukemia (ALL),35 diffuse large B-cell lymphoma (DLBCL)39 and multiple myeloma (MM),30 or both non-Hodgkin lymphoma (specifically, DLBCL and follicular lymphoma [FL]) and Hodgkin lymphoma.24 Three (21%) studies assessed the use of NGS testing strategies on patient management,24-26 while other studies used a variety of molecular techniques, such
as karyotyping, FISH, qPCR, RT-qPCR, or gene expression profile test. These tests were mostly evaluated to match patients to a specific therapy (i.e., as a companion diagnostic) \( n = 6; 43\% \) comparing a risk-stratified treatment approach for existing and novel therapies versus a conventional or no testing strategy.\(^{25-27,29,30,36}\) Other applications included monitoring of therapeutic response \( n = 5; 36\% \),\(^{28,31,32,34,37}\) or informing prognosis \( n = 2; 14\% \)^\(^{24,33}\) and treatment dosing \( n = 1; 7\% \).\(^{35}\) All five publications that assessed the test to monitor treatment were in CML for BCR-ABL1 transcript levels using either qPCR or RT-qPCR technology in determining treatment discontinuation with tyrosine kinase inhibitor (TKI) therapies (i.e., imatinib, dasatinib, and nilotinib).\(^{28,31,32,34,37}\) Seven (50\%) studies focused on first-line treatment,\(^{25,27-31,37}\) one study (7\%) on second-line treatment,\(^{36}\) and three (21\%) on multiple treatment lines either across the entire treatment pathway,\(^{26}\) within first-line and second-line treatment only,\(^{32}\) or in previously

| Annual discount rate | Uncertainty and sensitivity analysis | Data sources | Effectiveness data | Cost data | CHEERS score |
|----------------------|------------------------------------|--------------|-------------------|-----------|--------------|
| Not applicable       | One-way sensitivity analysis, probabilistic analysis | Literature sources | Public health insurance data, case costing data | 95% |
| 3%                   | One-way sensitivity analysis, probabilistic analysis, scenario analysis | Patient-level hospital medical records | Literature sources, hospital cost data, national health insurance data | 91% |
| 3%                   | One-way sensitivity analysis, scenario analysis | Literature sources | Physicians’ fee schedule | 95% |
| Not reported         | Not reported                        | Not applicable | Internal institution data | 42% |
| 3.5%                 | One-way sensitivity analysis, probabilistic analysis, scenario analysis | Literature sources | National health insurance data, clinical trial data | 100% |
| 5%                   | Scenario analysis                   | Not applicable | Internal institution data | 74% |
| 1.5\% (Health); 4\% (Costs) | One-way sensitivity analysis, scenario analysis | Literature sources | National health insurance data, clinical trial data | 91% |
| Not applicable       | Not reported                        | Not applicable | Administrative claims data | 83% |
| Not applicable       | Probabilistic analysis              | Not applicable | Administrative claims data | 83% |
| Not reported         | One-way sensitivity analysis, probabilistic analysis | Not applicable | Literature sources | 70% |
| Not reported         | One-way sensitivity analysis, scenario analysis | Not applicable | Literature sources, national health insurance data | 89% |
| Not reported         | One-way sensitivity analysis        | Not applicable | Internal institution data | 74% |
| 3%                   | Probabilistic analysis, scenario analysis | Literature sources | Physicians’ fee schedule, literature sources | 91% |
| Country specific discount rates | One-way sensitivity analysis | Patient-level clinical trial data | Clinical trial data, literature sources, national health insurance databases | 95% |
untreated and previously treated patient cohorts with no differentiation in treatment line for previously treated patients. 33 However, three (21%) publications did not report on the treatment line. 24,34,35 Four (57%) of the seven studies in first-line treatment only were on companion diagnostics 25,27,29,30 and three (43%) were for treatment monitoring. 28,31,37

Fourteen out of 17 different ESMO guideline documents for the management of different hematological malignancies included recommendations for either cytogenetic or molecular testing according to implication for clinical practice, clinical trials, and targeted trials from the ESMO guidelines as summarized in Table 2. Of which, four (29%) ESMO guidelines include biomarkers that have been the subject of health economic studies in AML, 25,27 CLL, 26,33 CML, 28,31,32,34,36,37 and MM 33 evaluated molecular biomarkers that were the subject of ESMO guidelines.

3.4 | Economic analysis

Studies were either full economic evaluations considering both health and economic outcomes (n = 7; 50%), 25-27,29,30,35,36 partial economic evaluations considering economic outcomes only (n = 6; 43%), 24,28,31,33,34,37 or a budget impact analysis (n = 1; 7%). 32 Of the seven full economic evaluations, two (29%) studies were cost-effectiveness analyses with life years (LY) as health outcome, 27,35 three (43%) studies were cost-utility analysis with QALY as health outcome, 25,29,30 and two (29%) studies were both a cost-effectiveness and cost-utility analysis. 26,36 Conversely, the six partial economic evaluations were comprised of five (83%) cost analyses 24,28,31,33,37 and one (17%) cost-minimization analysis assuming interventions are non-inferior in health outcomes. Five out of six (83%) publications on CML were partial economic evaluations 28,31,34,37 or a budget impact analysis, 32 with one (17%) publication in CML a cost-effectiveness and cost-utility analysis. 36

Most health economic studies utilized a decision analytic model (n = 9; 64%) (Table 3), 25,27,29,32,35,36 All five publications that did not use any modeling were either a cost analysis 24,28,33,37 or a cost-minimization analysis. 34 Studies were mostly assessed from the healthcare system perspective (n = 8; 57%), 25-28,30,35-37 followed by a payer (n = 3; 21%), 29,31,32 health service (n = 2; 14%), 24,33 and societal (n = 1; 7%) perspective. 34 Although Cayouella et al. 34 reported a societal perspective, it was classified as a health service perspective because only direct cost and indirect cost arising from health labor and equipment were accounted but not non-medical costs. Half (n = 7; 50%) of all studies applied a time horizon of less than 10 years, 25,27,28,32,35-37 and three (21%) studies used the lifetime analytic approach measuring the health outcomes and costs throughout the entire patient life duration in the study. 26,29,30 Four (29%) studies did not state a time horizon. 24,31,33,34

Many studies used multiple literature sources 26,27,29,35,36 or patient-level hospital medical records 25 for effectiveness data, with one study deriving model parameter input values from patient-level clinical trial data. 30

3.5 | Decision analytic model characteristics

Table 3 provides additional methodological characteristics and model-specific information. Among the nine model-based studies, cohort-level modeling techniques (n = 8; 89%) 25,27,29,32,35,36 were more common than patient-level models (n = 1; 11%). 29 The latter was a patient-level state-transition model (STM). 29 Cohort-level models were either decision trees (n = 3; 33%), 31,35,36 cohort-level state-transition models (STM) otherwise known as Markov models (n = 4; 44%), 26,27,30,32 or a two-part modeling approach encompassing both these techniques (n = 1; 11%). 25 Model structures were mostly health-state driven (n = 7; 78%) 25,27,29,31,35,36 using a series of health states such as progression-free survival, progressive disease, treatment response, adverse events and severity, relapse, and death. Two studies (33%) additionally defined health states for each treatment line in their model structure. 26,32 Relevant only to STM studies, cycle lengths were either 3 weeks (n = 1), 29 28 days/1 month (n = 3), 26,27,30 90 days (n = 1), 33 or 1 year (n = 1). 32

3.6 | Sensitivity analysis and validation efforts

Sensitivity analysis for the characterization of model assumptions and model-specific information. Among the nine model-based studies, cohort-level modeling techniques (n = 8; 89%) 25,27,29,32,35,36 were more common than patient-level models (n = 1; 11%). 29 The latter was a patient-level state-transition model (STM). 29 Cohort-level models were either decision trees (n = 3; 33%), 31,35,36 cohort-level state-transition models (STM) otherwise known as Markov models (n = 4; 44%), 26,27,30,32 or a two-part modeling approach encompassing both these techniques (n = 1; 11%). 25 Model structures were mostly health-state driven (n = 7; 78%) 25,27,29,31,35,36 using a series of health states such as progression-free survival, progressive disease, treatment response, adverse events and severity, relapse, and death. Two studies (33%) additionally defined health states for each treatment line in their model structure. 26,32 Relevant only to STM studies, cycle lengths were either 3 weeks (n = 1), 29 28 days/1 month (n = 3), 26,27,30 90 days (n = 1), 33 or 1 year (n = 1). 32

Seven (50%) studies incorporated a scenario analysis varying a combination of two or more model inputs. 25,27,29,32,34,36 Model validation efforts were reported in a single study. 26

3.7 | Cost and cost-effectiveness outcomes

Five (71%) out of seven cost-effectiveness publications suggested cost-effective use of healthcare resources when molecular biomarker tests were used as a companion diagnostic for identifying population groups most likely to respond to treatment. 25,27,29,30,36

Two of these publications evaluated between two diagnostic approaches in AML. One study compared between a multigene targeted genomic analysis and standard molecular analysis in determining optimal consolidation therapies following complete remission from induction chemotherapy for AML, with an ICER of Canadian dollars (CAD) $49 493/QALY gained and a 58% chance of cost-effectiveness at CAD$100 000/QALY. 25 Similarly, molecular genetic diagnostics used for the characterization FLT3-ITD, NPM1, and CEBPA mutational status were compared to conventional cytogenetic diagnostics for first-line treatment of AML, whereby the molecular genetic diagnostics strategy was cost-effective in Germany.
based on an ICER of US$59 136/LY gained and a willingness-to-pay range of one-to-three times Germany’s gross domestic product (GDP) per capita.27

The three other publications evaluated predictive biomarker testing against a “no testing” comparator. Firstly, a microarray platform for targeted second-line treatment (TKI therapies, interferon-alpha plus low-dose cytarabine, or HSCT) compared to a no testing strategy (dasatinib treatment for all patients) in CML was more effective and less costly in the Netherlands.36 Secondly, although no definitive conclusions were drawn, a favorable cost-effectiveness was suggested for a gene expression profile test to stratify patients with DLBCL into receiving either first-line novel treatment or chemotherapy based on patient’s germinal center B-cell-like subtype compared to the no testing strategy (chemotherapy for all patients) at an ICER of US$15 015/QALY in the US.29 Finally, a risk-stratified treatment approach (combination of International Staging System, FISH for t(4;14) and del(17p) and/or SKY92 gene expression classifier) for transplant-eligible patients with MM to differentiate between first-line bortezomib-based regimens and chemotherapy-based regimens compared to a no testing strategy (bortezomib-based regimens for all patients) was more effective and less costly across multiple European countries.30

Similarly, four (57%) out of seven partial economic evaluations and budget impact analysis studies showed that increased frequency of molecular monitoring of BCR-ABL1 in CML is associated with lower healthcare resource utilization and medical costs.28,31,32,37 This was likely due to TKI therapy discontinuation in patients who are no longer responsive to treatment or are likely to develop disease progression or adverse events.

Several economic evaluations reported assumptions regarding treatment effectiveness for associated therapies with companion diagnostics.26,29,36 Sensitivity analyses suggested that the cost-effectiveness of the molecular biomarker test used for treatment selection was more influenced by both the cost and long-term health benefits for treatments following testing, including quality of life, rates of treatment relapse, and mortality than the cost of the test itself.25,26

4 | DISCUSSION

This systematic review identified fourteen publications from the past decade investigating the cost and cost-effectiveness of complex molecular biomarker testing strategies in hematological malignancies. Companion diagnostics for AML, CML DLBCL, and MM were likely cost-effective, whereas regular molecular monitoring of BCR-ABL1 transcripts in CML with TKI therapy was likely cost-saving. Despite high compliance to reporting standards, the paucity of health economic studies precludes meaningful comparisons across studies, and therefore, the economic value of other testing strategies is not fully understood.

Health economic studies can be used to improve the availability of molecular biomarker tests and support their optimal allocation and delivery in health systems. Several studies in this review evaluated companion diagnostics used in a single line of treatment, typically first-line treatment. Of the economic evaluation studies that support the cost-effectiveness of companion diagnostics in hematological malignancies, SKY92 signature test measuring gene expression levels in MM has not yet been clinically recommended. Likewise, a multigene targeted genomic analysis was evaluated as cost-effective for AML, but not all genes in the panel are currently recommended in the ESMO clinical guidelines. Nevertheless, it is likely that companion diagnostics will become more prominent for patient clinical management with the expenditure of treatment contingent on the likelihood of patient response, especially as more novel, costly targeted therapies enter the market.3 However, as most studies are from European countries and from the healthcare system perspective, results may not be directly applicable to other settings. This review identified several other challenges, such as that the cost-effectiveness of these tests is sensitive to the long-term treatment outcomes, health state utility, rates of treatment relapse, and mortality along with the cost of associated treatment.25,26 Furthermore, studies suggest that appropriate adherence to the clinical recommendations of molecular monitoring of BCR-ABL1 transcripts in CML using either qPCR or RT-qPCR technologies may reduce the economic burden of the disease. These studies demonstrate the potential value of regular molecular monitoring and may encourage appropriate measures to better align real-world clinical testing practices with recommended clinical guidelines.38

With the publication scarcity in health economic studies of molecular biomarker tests for hematological malignancies, distinct research gaps are evident. Based on published ESMO clinical guidelines,39-54 not all molecular biomarkers that are recommended for testing have been investigated. For instance, no health economic studies have considered the predictive significance of IGHV mutation status testing prior to first-line therapy in CLL.53 Hematological malignancies such as myelodysplastic syndromes and myeloproliferative neoplasms were also absent. There is also a shortage of health economic research for NGS notwithstanding its utility regarding the molecular aspects of the World Health Organization (WHO) diagnostic classification for hematopoietic and lymphoid malignancies.55 Novel complex genomic testing was assessed in a cost analysis for targeted DNA sequencing in non-Hodgkin and Hodgkin lymphoma,24 a cost-effectiveness analysis genomic testing in CLL,26 and a cost-utility analysis of multigene targeted genomic analysis in AML.25 However, other than the study in AML, these interventions were either more expensive than other diagnostic strategies or not cost-effective. Unless further health economic research is developed for these genomics platforms, the capacity to widely embed genomics within clinical care for hematological malignancies will be further delayed.

Although the methodological quality of the health economic studies seems fair, there are several opportunities to expand the evidence base. Studies that either adopted a relatively short time horizon or single treatment-line evaluations may not fully account the impact of these tests on sequential clinical processes
or downstream consequences from changes to care from molecular biomarker testing.\textsuperscript{56,57} Therefore, the longer-term economic impacts on cancer management needs to be examined. This is, however, underpinned by availability of data sources needed to populate decision analytic models. Health outcomes from studies were mostly evidence driven from published clinical trials, with fewer studies using individual patient clinical, observational, or other real-world data. Health economic studies in precision medicine research are increasingly using real-world data to assess the effectiveness of interventions in practice, patient heterogeneity, and non-health outcomes associated with molecular diagnostics.\textsuperscript{58-60} This is a possible future direction for this field of clinical molecular biomarkers in blood cancers. Nonetheless, challenges in patient consent and data sharing may influence access to real-world patient-level health outcomes data for research, but guidance is available to incorporate such evidence into HTA for oncology and precision medicine.\textsuperscript{61,62} These technical issues are consistent with previous research commenting on the complexities in the design of economic evaluations of precision medicine (albeit not hematological malignancy specific).\textsuperscript{34,63-70}

This review has recognized that the limited number of health economic studies in recent years is concerning, but there is another layer of complexity to the conduct of health economic research for HTA purposes. This includes small market sizes given the rarity of many hematological malignancies,\textsuperscript{70} expensive drug prices, health economic outcomes above payor’s willingness-to-pay, and insufficient market incentives (evidenced by the small number of industry-funded research studies in this review), in addition to technical difficulties regarding evaluation design and data acquisition.\textsuperscript{71-73} While economic evaluations and budget impact analysis are conventionally focused on a single intervention on a single population using traditional value metrics such as health gains (i.e., LY and QALY), cost savings, and/or productivity,\textsuperscript{74,75} it is also important to consider other value elements beyond these core health outcomes that are a direct consequence of molecular biomarker tests.\textsuperscript{65,75-77} Technologies like NGS impart greater diagnostic certainty and generate patient information that supports present-day and future clinical decisions, with potential psychological gains and personal utility for which payors (and patients) may be willing to pay. HTA agencies are yet to extensively consider patient-centered value propositions, but value elements should be more akin to how molecular biomarker tests affect patients in making treatment choices. To incentivize research in this area and promote efficiency of health systems from these innovations over time, ongoing policy discussions will need to determine how payors can accept assessments of molecular biomarker tests in hematological malignancies consorted with the value of these services for patients.\textsuperscript{77,78}

There are limitations to this systematic review. Findings from this review are subjected to publication bias as there may be a bias toward publications with more favorable cost-effectiveness results in journals. Secondary publications of HTA reports across different healthcare systems were not considered, which may introduce unforeseen bias, but this review is focused on the publicly available economic literature. Moreover, the CHEERS checklist was used to assess the quality of reporting, but the checklist was not originally developed to score publications, thereby introducing subjectivity in methodology appraisal. Finally, with a range of analytical methods assessing the health outcomes and costs attributable to these interventions, the study results were summarized at the discretion of the reviewers.

4.1 Conclusions

There are a limited number of health economic studies for molecular biomarker tests in hematological malignancies to facilitate clinical incorporation into routine clinical management. Although the cost and cost-effectiveness evidence in this disease were promising, further research is needed to examine the health economic impact of molecular biomarker tests across different biomarkers and technologies, including NGS, to support implementation and reimbursement decisions.

ACKNOWLEDGMENTS

The authors would like to thank Smaro Lazarakis, Librarian, Health Sciences Library at the Royal Melbourne Hospital, the Royal Women’s Hospital, Peter MacCallum Cancer Centre, and Victorian Mental Health, for critically reviewing and advising on the selection of databases and search strategy.

CONFLICT OF INTEREST

The authors declare no competing financial interests.

AUTHOR CONTRIBUTIONS

Contribution: All authors contributed to the review protocol study; M.V., K.D., and M.I.J. prepared the search strategy approved by all authors; M.V. performed the search strategy; M.V. and K.D. conducted the screening and selection process. M.V. extracted and analyzed the data; M.V., K.D., and M.I.J. interpreted the results and M.V. prepared the first draft of the manuscript and was critically reviewed by all authors; and all authors approved the submitted final version of the manuscript.

DATA AVAILABILITY STATEMENT

All data generated or analyzed during this study are included in this published article and its supplementary information files.

ORCID

Martin Vu \url{https://orcid.org/0000-0001-5918-1692}
Koen Degeling \url{https://orcid.org/0000-0001-7487-2491}
Ella R. Thompson \url{https://orcid.org/0000-0001-5206-5111}
Piers Blombery \url{https://orcid.org/0000-0002-9902-0022}
Maarten J. IJzerman \url{https://orcid.org/0000-0001-5788-5805}
REFERENCES

1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.

2. Pulte D, Jansen L, Brenner H. Changes in long term survival after diagnosis with common hematologic malignancies in the early 21st century. Blood Cancer J. 2020;10(5):56.

3. Hou J-Z, Ye JC, Pu JJ, et al. Novel agents and regimens for hematologic malignancies: recent updates from 2020 ASH annual meeting. J Hematol Oncol. 2021;14(1):66.

4. American Cancer Society. Cancer facts & figures 2021. 2021; https://www.cancer.org/research/cancer-facts-statistics/cancer-facts-figures/cancer-facts-figures-2021.html Accessed 22 June 2021.

5. Burns R, Leal J, Sullivan R, Luengo-Fernandez R. Economic burden of malignant blood disorders across Europe: a population-based cost analysis. Lancet Haematol. 2016;3(8):e362-370.

6. Hussaini M. Biomarkers in hematological malignancies: a review of molecular testing in hematology pathology. Cancer Control. 2015;22(2):158-166.

7. Alonso CM, Llop M, Sargas C, et al. Clinical utility of a next-generation sequencing panel for acute myeloid leukemia diagnostics. J Mol Diagn. 2019;21(2):228-240.

8. Burd A, Levine RL, Ruppert AS, et al. Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. Nat Med. 2020;26(12):1852-1858.

9. Hallek M, Cheson BD, Cavosky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745-2760.

10. Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-447.

11. Fiorentini A, Capelli D, Saraceni F, Menotti D, Poloni A, Olivieri A. The time has come for targeted therapies for AML: lights and shadows. Oncol Ther. 2020;8(1):13-32.

12. Morash M, Mitchell H, Beltran H, Elemento O, Pathak J. The role of next-generation sequencing in precision medicine: a review of outcomes in oncology. J Pers Med. 2018;8(3):30.

13. Coccaro N, Anelli L, Zagaria A, Specchia G, Albano F. Next-generation sequencing in acute lymphoblastic leukemia. Int J Mol Sci. 2019;20(12):2929.

14. Shabaruddin FH, Fleeman ND, Payne K. Economic evaluations of personalized medicine: existing challenges and current developments. Pharmacogenomics Pers Med. 2015;8:115-126.

15. Bacher U, Shumilov E, Flach J, et al. Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use. Blood Cancer J. 2018;8(11):113.

16. De Maria Marchiano R, Di Sante G, Piro G, et al. Translational research in the era of precision medicine: where we are and where we will go. J Pers Med. 2021;11(3):216.

17. Gavan SP, Thompson AJ, Payne K. The economic case for precision medicine. Expert Rev Precis Med Drug Dev. 2018;3(1):1-9.

18. Doble B. Budget impact and cost-effectiveness: can we afford precision medicine in oncology? Scand J Clin Lab Invest Suppl. 2016;245:56-S11.

19. European Society of Medical Oncology. ESMO clinical practice guidelines: Haematological malignancies. 2021; https://www.esmo.org/guidelines/haematological-malignancies Accessed 22 June 2021.

20. Institute for Health Metrics and Evaluation. Global Burden of Disease (GBD). 2021; http://www.healthdata.org/gbd/2019 Accessed 22 June 2021.

21. Organisation for Economic Co-operation and Development. Consumer price indices (CPIs) - complete database. 2021; https://stats.oecd.org/Index.aspx?DataSetCode=PRICES_CPI Accessed 8 March 2021.

22. Organisation for Economic Co-operation and Development. Purchasing power parities for GDP and related indicators. 2021; https://stats.oecd.org/index.aspx?DataSetCode=PPPGDP Accessed 8 March 2021.

23. Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health. 2013;16(2):231-250.

24. Costa S, Regier DA, Meissner B, et al. A time-and-motion approach to micro-costing of high-throughput genomic assays. Curr Oncol. 2016;23(5):304-313.

25. Cressman S, Karnas A, Hogge DE, et al. Economic impact of genetic diagnostics for intermediate-risk acute myeloid leukemia. Br J Haematol. 2016;174(4):526-535.

26. Buchan J, Wordsworth S, Clifford R, et al. Using genomic information to guide ibrutinib treatment decisions in chronic lymphocytic leukemia: a cost-effectiveness analysis. Pharmacoeconomics. 2017;35(8):845-858.

27. Hörster L, Schlenk RF, Stadler M, et al. Cost-effectiveness of methods in personalized medicine. Results of a decision-analytic model in patients with acute myeloid leukemia with normal karyotype. Leuk Res. 2017;62:84-90.

28. Latremouille-Viu D, Guerin A, Gagnon-Sanschagrin P, Dea K, Cohen MG, Joseph GJ. Health care resource utilization and costs in patients with chronic myeloid leukemia with better adherence to tyrosine kinase inhibitors and increased molecular monitoring frequency. J Manag Care Spec Pharm. 2017;23(2):214-224.

29. Chen Q, Staton AD, Ayer T, Goldstein DA, Koff JL, Flowers CR. Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma. Leuk Lymphoma. 2018;59(7):1700-1709.

30. Gaultney JG, Ng TW, Uyl-de Groot CA, et al. Potential therapeutic and economic value of risk-stratified treatment as initial treatment of multiple myeloma in Europe. Pharmacogenomics. 2018;19(3):213-226.

31. Jabbour EJ, Siegertal LR, Lin J, Lingohr-Smith M, Menges B, Makenbaeva D. Economic value of regular monitoring to guide ibrutinib treatment decisions in chronic lymphocytic leukemia based on an economic model. J Med Econ. 2018;21(10):1036-1040.

32. Yamazaki K, Inagaki N, Moldaver D, Viana R, Kimura S. Budget impact analysis of treatment-free remission in nilotinib-treated Japanese chronic myeloid leukemia patients. Cancer Sci. 2020;111(7):2526-2535.

33. Al Zaabi EA, Fernandez LA, Sadek IA, Riddell DC, Greer WL. Multiplex ligation-dependent probe amplification versus multi-probe fluorescence in situ hybridization to detect genomic aberrations in chronic lymphocytic leukemia: a tertiary center experience. J Mol Diagn. 2010;12(2):197-203.

34. Cayuela J-M, Macintyre E, Darlington M, et al. Cartridge-based automated BCR-ABL1 mRNA quantification: solving the issues of standardization, at what cost? Haematologica. 2011;96(5):664-671.

35. Donnan JR, Ungar WJ, Mathews M, Hancock-Howard RL, Rahman P. A cost effectiveness analysis of thiopurine methyltransferase testing for guiding 6-mercaptopurine dosing in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2011;57(2):231-239.

36. Gaultney JG, Sanhueza E, Janssen JJ, Redekop WK, Uyl-de Groot CA. Application of cost-effectiveness analysis to demonstrate the potential value of companion diagnostics in chronic myeloid leukemia. Pharmacogenomics. 2011;12(3):411-421.

37. Guérin A, Chen L, Dea K, Wu EQ, Goldberg SL. Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia. J Med Econ. 2014;17(2):89-98.
38. Goldberg SL, Cortes JE, Gambacorti-Passerini C, et al. Cytogenetic and molecular testing in patients with chronic myeloid leukemia (CML) in a prospective observational study (SIMPLICITY). *J Clin Oncol*. 2014;32(15 suppl):7050.

39. d'Amore F, Gaudard P, Trümper L, et al. Peripheral T-cell lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2015;26(suppl 5):v108-v115.

40. Robak T, Matutes E, Catovsky D, Zinzani PL, Buske C. Hairy cell leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2015;26(suppl 5):v100-v107.

41. Tilly H, Gomes da Silva M, Vitolo U, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2015;26(suppl 5):v116-v125.

42. Vannucchi AM, Barbui T, Cervantes F, et al. Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2015;26(suppl 5):v85-v99.

43. Hoelzer D, Bassan R, Dombret H, Fielding A, Ribera JM, Buske C. Acute lymphoblastic leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2016;27(suppl 5):v69-v82.

44. Dreyling M, Campo E, Hermine O, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2017;28(suppl 4):iv62-iv71.

45. Hochhaus A, Saussele S, Rosti G, et al. Chronic myeloid leukemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2017;28(suppl 4):iv41-iv51.

46. Eichnauer DA, Aleman BMP, André M, et al. Hodgkin lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2018;29(suppl 4):iv19-iv29.

47. Kaatrits E, Leblond V, Dimopoulos MA, et al. Waldenström’s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2018;29(suppl 4):iv41-iv50.

48. Willemsen R, Hodak E, Zinzani PL, Specht L, Laddetto M. Primary cutaneous lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2018;29(suppl 6):iv30-iv40.

49. Heuser M, Ofran Y, Boissel N, et al. Acute myeloid leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2020;31(6):679-712.

50. Zucca E, Arcaini L, Buske C, et al. Marginal zone lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2020;31(1):17-29.

51. Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2021;32(3):309-322.

52. Dreyling M, Ghelmini M, Rule S, et al. Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2021;32(3):298-308.

53. Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2021;32(1):23-33.

54. Fenaux P, Haase D, Santini V, Sanz GF, Platzbecker U, Mey U. Myelodysplastic syndromes: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2021;32(2):142-156.

55. Schwarze K, Buchanan J, Taylor JC, Wordsworth S. Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature. *Genet Med*. 2018;20(10):1122-1130.

56. Kim DDH. Are we ready to use precision medicine in chronic myeloid leukemia practice? *Haematologica*. 2019;104(12):2327-2329.

57. Moia R, Patriarca A, Schipani M, et al. Precision medicine management of chronic lymphocytic leukemia. *Cancers*. 2020;12(3):642.

58. Cahan A, Cimino JJ. Improving precision medicine using individual patient data from trials. *CMAJ*. 2017;189(5):E204-E207.

59. Terkola R, Antoñanzas F, Postma M. Economic evaluation of personalized medicine: a call for real-world data. *Eur J Health Econ*. 2017;18(9):1065-1067.

60. Faulkner E, Holtorf A-P, Walton S, et al. Being precise about precision medicine: what should value frameworks incorporate to address precision medicine? A report of the personalized precision medicine special interest group. *Value Health*. 2020;23(5):529-539.

61. Deverka PA, Douglas MP, Phillips KA. Use of real-world evidence in US payer coverage decision-making for next-generation sequencing-based tests: Challenges, opportunities, and potential solutions. *Value Health*. 2020;23(5):540-550.

62. Greshock J, Lewi M, Hartog B, Tendler C. Harnessing real-world evidence for the development of novel cancer therapies. *Trends Cancer*. 2020;6(11):907-909.

63. Marshall DA, Grazziotin LR, Regier DA, et al. Addressing challenges of economic evaluation in precision medicine using dynamic simulation modeling. *Value Health*. 2020;23(5):566-573.

64. Annemans L, Redekop K, Payne K. Current methodological issues in the economic assessment of personalized medicine. *Value Health*. 2013;16(6 suppl):S20-S26.

65. Buchanan J, Wordsworth S, Schuh A. Issues surrounding the health economic evaluation of genomic technologies. *Pharmacogenomics*. 2013;14(15):1833-1847.

66. Degeling K, Koffijberg H, Ijzerman MJ. A systematic review and checklist presenting the main challenges for health economic modeling in personalized medicine: towards implementing patient-level models. *Expert Rev Pharmacoeconom Outcomes Res*. 2017;17(1):17-25.

67. Vellekoop H, Huygens S, Versteegh M, et al. Guidance for the harmonisation and improvement of economic evaluations of personalised medicine. *Pharmacoeconomics*. 2021;39(7):771-788.

68. Yang Y, Abel L, Buchanan J, Fanshawe T, Shinkins B. Use of decision modelling in economic evaluations of diagnostic tests: an appraisal and review of health technology assessments in the UK. *Pharmacoecon Open*. 2019;3(3):281-291.

69. Phillips KA, Deverka PA, Marshall DA, et al. Methodological issues in assessing the economic value of next-generation sequencing tests: many challenges and not enough solutions. *Value Health*. 2018;21(9):1033-1042.

70. Weymann D, Dragoljovic N, Pollard S, Regier DA. Allocating healthcare resources to genomic testing in Canada: latest evidence and current challenges. *J Community Genet*. 2019. 10.1007/s12687-019-00428-5.

71. Garrison LP, Austin MJF. The economics of personalized medicine: a model of incentives for value creation and capture. *Ther Innov Regul Sci*. 2007;41(4):501-509.

72. Faulkner E, Annemans L, Garrison LP, et al. Challenges in the development and reimbursement of personalized medicine payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group. *Value Health*. 2012;15(8):1162-1171.

73. Towsie A, Garrison LP Jr. Economic incentives for evidence generation: promoting an efficient path to personalized medicine. *Value Health*. 2013;16(6 suppl):S39-43.

74. Lakdawalla DN, Doshi JA, Garrison LP Jr, Phelps CE, Basu A, Danzon PM. Defining elements of value in health care—a health economics approach: an ISPOR special task force report [3]. *Value Health*. 2018;21(2):131-139.

75. Towsie A, Garrison L. Value assessment in precision cancer medicine. *J Cancer Policy*. 2017;11:48-53.

76. Garrison LP Jr, Towsie A. A strategy to support efficient development and use of innovations in personalized medicine and precision medicine. *J Manag Care Spec Pharm*. 2019;25(10):1082-1087.
facilitate bringing this technology into healthcare systems. Public Health Genomics. 2019;22(1–2):8-15.

78. Love-Koh J, Peel A, Rejon-Parrilla JC, et al. The future of precision medicine: potential impacts for health technology assessment. Pharmacoeconomics. 2018;36(12):1439-1451.

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Vu M, Degeling K, Thompson ER, Blombery P, Westerman D, IJzerman MJ. Health economic evidence for the use of molecular biomarker tests in hematological malignancies: A systematic review. Eur J Haematol. 2022;00:1–17. https://doi.org/10.1111/ejh.13755